

**CLAIMS AMENDMENTS**

Please cancel claims 1-6, 8, 16 and 21-33, without prejudice.

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claim 1-6 (Canceled)

Claim 7 (Currently amended): ~~The~~ An antisense oligonucleotide of ~~claim 6~~ comprising a sequence substantially complementary to ~~nucleotides selected from the group of: (a) 124 to 141 of the sequence of human KSR, corresponding to 151 to 168 of the sequence of mouse KSR (SEQ ID NO:3), (b) 154 to 171 of the sequence of human KSR (SEQ ID NO:27) (c) 181 to 198 of the sequence of mouse KSR (SEQ ID NO: 4); and (d) 187 to 204 of the sequence of human KSR, corresponding to 214 to 231 of the sequence of mouse KSR (SEQ ID NO: 5), wherein the oligonucleotide is from about 8 to about 50 nucleotides in length.~~

Claim 8 (Canceled)

Claim 9 (Currently amended): The oligonucleotide of claim ~~[[1]]~~ 7 labeled with a detectable label.

Claim 10 (Currently amended): The oligonucleotide of claim ~~[[1]]~~ 9 wherein the label is selected from enzymes, ligands, chemicals which fluoresce and radioactive elements.

Claim 11 (Currently amended): The oligonucleotide of claim ~~[[1]]~~ 7

wherein said oligonucleotide comprises at least one phosphorothioate linkage.

Claim 12 (Currently amended): A recombinant DNA molecule comprising a nucleic acid sequence which encodes on transcription an antisense RNA from about 8 to about 50 nucleotides in length which is complementary to mammalian KSR-RNA or a portion thereof SEQ ID NO:5.

Claim 13 (Original): The recombinant DNA molecule of claim 12, wherein said nucleic acid sequence is operatively linked to a transcription control sequence.

Claim 14 (Original): A cell line transfected with the recombinant DNA molecule of claim 13.

Claim 15 (Currently amended): An expression vector capable of expressing a nucleic acid which is substantially complementary to ~~the coding sequence of KSR-RNA, or a portion/fragment thereof~~ SEQ ID NO:5, wherein said ~~oligonucleotide/nucleic acid~~ inhibits the expression of KSR and is from about 8 to about 50 nucleotides in length.

Claim 16 (Canceled)

Claim 17 (Currently amended): A pharmaceutical composition comprising a therapeutically effective amount of ~~an~~ the antisense oligonucleotide of claim ~~[[1]]~~ 7 and a pharmaceutically acceptable carrier or diluent.

Claim 18 (Currently amended): A composition comprising the

oligonucleotide of claim ~~[[1]]~~ 7 and a pharmaceutically acceptable carrier or diluent.

Claim 19 (Currently amended): A composition comprising one or more chemotherapeutic or radiotherapeutic agent and ~~an~~ the oligonucleotide of claim 7, which is targeted to a mRNA encoding mammalian KSR and which wherein the oligonucleotide inhibits KSR expression.

Claim 20 (Currently amended): A composition comprising an expression vector and a pharmaceutically acceptable carrier or diluent, wherein said expression vector is capable of expressing a nucleic acid which is substantially complementary to ~~the coding sequence of KSR RNA, or a portion/fragment thereof~~ SEQ ID NO:5, wherein said nucleic acid inhibits the expression of KSR and is from about 8 to about 50 nucleotides in length.

Claim 21-33 (Canceled).

Claim 34 (New): The oligonucleotide of claim 7, wherein the oligonucleotide is from about 10 to about 30 nucleotides in length.

Claim 35 (New): The oligonucleotide of claim 34, wherein the oligonucleotide is from about 15 to about 25 nucleotides in length.

Claim 36 (New): The oligonucleotide of claim 7, wherein the sequence is complementary to SEQ ID NO:5.

Claim 37 (New): The oligonucleotide of claim 7, which is complementary to SEQ ID NO:5 and is 18 nucleotides in length.

Claim 38 (New): The oligonucleotide of claim 7, which comprises a modified backbone.

Claim 39 (New): A pharmaceutical composition comprising a therapeutically effective amount of the antisense oligonucleotide of claim 11 and a pharmaceutically acceptable carrier or diluent.

Claim 40 (New): A composition comprising the oligonucleotide of claim 11 and a pharmaceutically acceptable carrier or diluent.

Claim 41 (New): A composition comprising one or more chemotherapeutic or radiotherapeutic agent and the oligonucleotide of claim 11, wherein the oligonucleotide inhibits KSR expression.

Claim 42 (New): The oligonucleotide of claim 37, which is a phosphorothioate oligodeoxynucleotide.

Claim 43 (New): The oligonucleotide of claim 7, which is an oligodeoxynucleotide.

Claim 44 (New): The oligonucleotide of claim 38, wherein the modified backbone is selected from a phosphorothioate, phosphotriester, methyl phosphonate, polyamide, and a morpholino backbone.